<DOC>
	<DOC>NCT02346721</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) administered for 12 weeks in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection that previously participated in the Gilead-sponsored study GS-US-342-1138.</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy Was administered placebo to match SOF/VEL in Gilead study GSUS3421138 HCV RNA ≥ 10^4 IU/mL at screening Classification as treatment naive or treatment experienced Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Current or prior history of clinicallysignificant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol; individuals currently under evaluation for a potentially clinicallysignificant illness (other than HCV) are also excluded. Screening electrocardiogram (ECG) with clinically significant abnormalities Laboratory results outside of acceptable ranges at screening Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>SOF/GS-5816</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>